VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of novel small molecule product candidates targeting Toll-like receptor 8 (TLR8) for cancer.from http://www.ventirx.com/about/index.html
Patents 141show all
- 53A61K - Preparations for medical, dental, or toilet purposes
- 40C07D - Heterocyclic compounds
- 15B82Y - Specific uses or applications of nanostructures
- 14C07K - Peptides
Clinical Trials 1show all
SEC Filings show all
Crunchbase Investment Rounds
|Date||Amount||Round||Valuation||Lead Investor||Other Investors|
|2014-09-23||$50,602,514||Series B||ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, MedImmune Ventures, Celgene|
|2010-01-13||$25,000,000||Series A||MedImmune Ventures||ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates|
|2007-03-06||$26,600,000||Series A||Frazier Healthcare Partners||Domain Associates, ARCH Venture Partners|
SEC Form D Funding Events
- Robert M. Hershberg, M.D., Ph.D.
Executive Officer, Director
- Patrick Heron
- Nicole Vitullo
- Steven Gillis, Ph.D.
- Elliot Grossbard, M.D.
- Atul Saran
- Kent Snyder
- Ron Laufer
- Kathleen Fanning